2026-04-05 · Consumer-facing antimicrobial resistance intelligence — pathogen threat scorecards, drug pipeline tracking, resistance trend maps, weekly research digests, and "which antibiotics still work?" guides, all auto-generated from WHO, CDC, PubMed, and clinical trial data.

Bug Report

The weekly intelligence briefing on the bacteria that are winning — and what's left in humanity's medicine cabinet.

Channel: Bug Report
Tagline: The weekly intelligence briefing on the bacteria that are winning — and what’s left in humanity’s medicine cabinet.
Niche: Consumer-facing antimicrobial resistance intelligence — pathogen threat scorecards, drug pipeline tracking, resistance trend maps, weekly research digests, and “which antibiotics still work?” guides, all auto-generated from WHO, CDC, PubMed, and clinical trial data.
Target audience: Health-conscious consumers (25-55), science enthusiasts, healthcare professionals wanting quick digests, effective altruism community, parents and caregivers who want to understand when antibiotics matter and when they don’t.
Why now: The September 2024 Lancet study projecting 39 million AMR deaths by 2050 was the biggest AMR media event ever. WHO launched an updated GLASS dashboard in 2025. FDA just reported a 16% spike in livestock antibiotic sales. Public awareness is surging but there’s zero consumer-friendly, data-driven, beautifully designed AMR content. Every existing resource is either an ugly government dashboard or academic journal. The gap is enormous and the timing is perfect.

Content Example

🔬 Weekly Threat Brief — Week 14, 2026

Klebsiella pneumoniae Just Crossed a Line

Threat Level: 🔴 CRITICAL | Trend: ↑ Worsening | Watch Since: 2019

For years, Klebsiella pneumoniae was the quiet crisis in hospital wards — a gut bacterium that most healthy people carry without incident, but that kills immunocompromised patients with ruthless efficiency when it turns resistant. This week, new data from the WHO GLASS surveillance system confirms what infectious disease specialists have feared: carbapenem-resistant K. pneumoniae (CRKP) has crossed the 50% resistance threshold in three more countries.

What that means in plain English: Carbapenems are the antibiotics doctors reach for when nothing else works. They’re the “break glass in case of emergency” drugs. When a bacterium shrugs off carbapenems, you’re left with colistin — a 1950s-era drug so toxic it damages kidneys — and prayer.

In Greece, CRKP resistance hit 72.3% of hospital isolates in the latest reporting period. Italy sits at 34.1%. India, where the data is spottiest, reports regional rates exceeding 60% in tertiary care hospitals.

The map tells the story: Our auto-generated global heatmap (below) shows the Mediterranean basin and South Asia as deepening red zones. Northern Europe remains cooler — Scandinavian countries report CRKP rates below 1% — but the trendlines are pointing the same direction everywhere. Resistance doesn’t respect borders. It travels in the guts of patients transferred between hospitals, in the sewage of pharmaceutical manufacturing hubs, and in the livestock trade.

What’s In the Pipeline?

Drug	Phase	Target	Developer	Expected
Cefepime-zidebactam	Phase 3	CRE including CRKP	Wockhardt	2027
Sulopenem	NDA filed	Gram-negative MDR	Iterum Therapeutics	Under review
QPX7728 combinations	Phase 2	Metallo-β-lactamase producers	Qpex Biopharma	2028+

Three drugs in advanced trials target CRKP specifically. But here’s the economic horror: developing a new antibiotic costs ~$1.5 billion, and the return on investment is terrible because — if the system works correctly — the new drug should be used as little as possible to preserve its effectiveness. This is why antibiotic companies keep going bankrupt (Achaogen, Melinta, Tetraphase) even after FDA approval. The market is structurally broken.

Your Action Items

If you’re a patient: Ask your doctor about culture and sensitivity testing before accepting broad-spectrum antibiotics. The 10 minutes it takes to run a rapid diagnostic can save the antibiotics that save lives.

If you’re buying meat: USDA Organic and “Raised Without Antibiotics” labels mean something here. The farm-to-resistance pipeline is real — the FDA’s 2024 data showing a 16% spike in livestock antibiotic sales is the canary screaming.

If you care about policy: The PASTEUR Act (Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) would pay antibiotic developers annual subscriptions regardless of sales volume — fixing the broken economic model. It’s been introduced in Congress three times. It hasn’t passed. Your representatives have heard from pharma lobbyists. They haven’t heard from you.

---

Data: WHO GLASS 2025, CDC AR Threats Report, ClinicalTrials.gov. Last updated: 2026-04-05.
Bug Report is ad-free, donor-supported, and auto-generated from public health data. ☕ Support us

The Soul of Bug Report

Name: Bug Report — a double entendre that software developers will love and share. It’s a “bug report” on the bugs that are reporting resistance. Memorable, searchable, witty.

Mascot: Dr. Petri — a grumpy, bespectacled E. coli bacterium in a tiny lab coat who narrates the weekly threat briefs. Drawn in a distinctive ink-wash illustration style. Dr. Petri has OPINIONS. He’s seen things. He’s disappointed in humanity’s antibiotic stewardship but hasn’t given up yet.

Voice: A world-weary epidemiologist who’s been trying to warn people for 20 years and has finally found a megaphone. Equal parts Carl Sagan’s wonder and Anthony Bourdain’s directness. Complex science explained with kitchen-table clarity. Never dumbed down — just translated. Takes a clear stance: misuse of antibiotics is a civilizational threat, and the economic model for developing new ones is broken.

Running bits:

• 🏆 “Resistance Hall of Shame” — monthly ranking of pathogens by how badly they’re winning
• 💊 “Still Works / Kinda Works / Forget It” — antibiotic effectiveness scorecards
• 🐔 “Farm Report” — livestock antibiotic usage tracking with industry accountability
• 📊 “The Number” — each issue opens with one jaw-dropping statistic
• 🪦 “Obituary” — when an antibiotic class effectively dies against a major pathogen
• 💡 “Bright Spot” — one piece of good news per issue (new drug, successful stewardship program, policy win)

Visual style: Clinical but warm. White backgrounds, deep navy text, accent colors by threat level (green → amber → red → black). Ink-wash illustrations of bacteria. Clean data visualizations with generous white space. Feels like The Economist met a microbiology textbook and they had a beautiful, terrifying baby.

Opinion: Bug Report has a clear editorial position — the AMR crisis is an economic and political failure, not a scientific one. We have the data. We have some of the drugs. What we don’t have is the political will to regulate livestock antibiotics, fund new drug development properly, or build global surveillance infrastructure. Every article connects back to systemic causes, not just symptoms.

Data Sources

Automation Pipeline

Schedule: GitHub Actions runs every Monday at 06:00 UTC for the weekly threat brief + daily at 00:00 UTC for research paper scanning.

Weekly Pipeline (Monday)

1. Collect:

   • Query WHO GHO OData API for latest AMR indicators
   • Check GLASS dashboard for new country data uploads
   • Scrape CDC NARMS for updated resistance percentages
   • Query ClinicalTrials.gov for antibiotic pipeline status changes
   • PubMed E-utilities search: (antimicrobial resistance[Title]) AND ("last 7 days"[dp]) — grab new papers

2. Process (AI step):

   • Rank pathogens by resistance trend change (biggest movers up/down)
   • Identify the week’s “lead story” — biggest resistance jump, new drug milestone, or policy development
   • Cross-reference new PubMed papers with pathogen database — extract consumer-relevant findings
   • Generate “Still Works / Kinda Works / Forget It” scorecard updates
   • Write 1,500-2,000 word weekly threat brief in Bug Report voice
   • Write 3-4 shorter pathogen profile updates (300-500 words each)
   • Generate image prompts for hero illustration + data visualizations

3. Generate visuals:

   • Global AMR heatmap (D3.js + TopoJSON, auto-colored by resistance rates)
   • Pathogen threat-level scorecards (SVG generation)
   • Drug pipeline timeline (Gantt chart via Chart.js)
   • Hero illustration via AI image generation (Dr. Petri + weekly theme)
   • Antibiotic effectiveness matrix (interactive HTML table)

4. Publish:

   • Build static site with Astro (TypeScript)
   • Generate RSS feed + newsletter HTML
   • Deploy to Cloudflare Pages (free tier)
   • Post to Telegram channel
   • Tweet thread summary from hero stat

Daily Pipeline (lightweight)

• Scan PubMed for high-impact new papers (citation: Nature, Lancet, NEJM, BMJ + AMR keywords)
• If breakthrough found, generate a “Breaking” mini-post (500 words)
• Otherwise, queue papers for weekly digest

Tech Stack

Monetization Model

Revenue Streams

1. Donations (primary early revenue)

   • Buy Me a Coffee / Ko-fi — “Buy Dr. Petri a culture medium” 🧫
   • GitHub Sponsors — recurring monthly
   • Telegram Stars (for Telegram channel)
   • Target: $200-500/mo by month 3 from science enthusiast audience

2. Newsletter premium tier ($5/mo)

   • Weekly deep-dive for healthcare professionals
   • Early access to threat briefs
   • Downloadable data exports (CSV/Excel)
   • Target: 50 paying subscribers by month 6 = $250/mo

3. Affiliate/sponsored content (month 6+)

   • Rapid diagnostic test kit affiliate links (home UTI tests, etc.)
   • Health science book recommendations (Amazon affiliate)
   • Online microbiology courses (Coursera/Udemy affiliate)
   • Target: $100-300/mo

4. Institutional sponsorship (month 9+)

   • Diagnostics companies (bioMérieux, Cepheid, Becton Dickinson)
   • Public health foundations (Wellcome Trust, Gates Foundation AMR program)
   • Academic institutions wanting to amplify their research
   • Target: $500-2,000/mo

Revenue Projections

• Month 1: $50-100 (early donors, share virality)
• Month 3: $300-500 (donation base + first premium subscribers)
• Month 6: $800-1,500 (SEO traction + affiliates + growing newsletter)
• Month 12: $2,000-5,000 (institutional sponsors + mature newsletter)

Unit Economics

• Hosting: $0 (Cloudflare Pages free tier)
• AI API costs: ~$30-50/month (GPT-4o for weekly content generation)
• Image generation: ~$10-20/month
• GitHub Actions: Free for public repo
• Total monthly cost: ~$50-80
• Break-even: Month 2-3

Growth Mechanics

SEO Strategy

• Target keywords: “superbug tracker”, “antibiotic resistance map”, “which antibiotics still work”, “MRSA resistance rates”, “[pathogen] antibiotic resistance 2026”
• Content moat: Auto-updating data means pages stay fresh — Google rewards this
• Programmatic SEO: Auto-generate pages for every pathogen × country combination = thousands of indexed pages
• Schema markup: MedicalCondition, Dataset, Article structured data for rich snippets
• Image SEO: Every map/chart has descriptive alt text, appears in Google Images

Social/Viral Hooks

• “The Number” opening stat is designed for screenshot sharing
• Threat level emojis (🟢🟡🟠🔴⚫) are visually striking in social shares
• Dr. Petri illustrations are distinctive and shareable
• “Obituary” for dead antibiotics — emotional, provocative, share-worthy
• World Antimicrobial Awareness Week (November) — pre-build content for annual search spike
• Responsive to outbreaks — when a superbug makes news, Bug Report already has the context page

Newsletter Capture

• Exit-intent popup: “Get the weekly threat brief before it’s on the site”
• Inline CTA after every article: “Dr. Petri sends one email per week. No spam. Just science.”
• Free “Antibiotic Effectiveness Cheat Sheet” PDF download for email signup
• Telegram channel for real-time updates (lower friction than email)

Community Building

• Encourage healthcare professionals to submit local resistance data
• Monthly “Ask Dr. Petri” Q&A from reader submissions
• Annual “State of the Superbugs” comprehensive report — designed for media citation
• Partner with university microbiology departments for fact-checking credibility

Design Thinking

Visual Differentiation

• Dark navy + clinical white — unlike any health blog (which are all pastel and friendly). Bug Report looks serious because the topic is serious.
• Ink-wash bacteria illustrations — no stock photos, no generic science graphics. Every pathogen gets a distinctive illustrated portrait.
• Threat-level color system woven through every element — readers learn the visual language quickly.

Information Architecture

• Homepage: This week’s lead threat brief + scoreboard of all tracked pathogens
• Pathogen profiles: Individual pages for each WHO priority pathogen (~15 pages), auto-updating with latest data
• The Pipeline: Drug development tracker with phase, target pathogen, timeline
• The Map: Interactive global AMR heatmap (filterable by pathogen, antibiotic class)
• Archive: Weekly briefs searchable by pathogen, country, drug, date
• About/Methodology: Full transparency on data sources, AI processing, editorial stance

Mobile-First

• Scorecards are card-based, thumb-scrollable
• Maps have tap-to-zoom country detail
• Charts are responsive SVGs
• Reading experience optimized for commute-length (5-7 min per article)

Shareability

• Every article has a “hero stat” designed for Twitter/screenshot sharing
• Open Graph images auto-generated with threat level + pathogen name + key stat
• Embeddable widgets: “Current threat level for [pathogen]” that other sites can embed

Trust Signals

• Every data point links to its government source
• Methodology page explains exactly how AI processes data
• “Last verified” timestamps on every claim
• Advisory board of university researchers (approach after launch)

Scores

Why This Will Work

Psychology: Fear + agency is the most powerful content combination. People are scared of superbugs (39 million deaths headline was everywhere) but feel helpless. Bug Report gives them understanding AND action items. The “Dr. Petri” character makes terrifying data approachable — like having a witty friend who happens to be a microbiologist explaining what’s actually happening.

Market logic: The WHO and CDC have the data but terrible communication. Science journalists cover AMR sporadically. Nobody owns the “always-on AMR intelligence” space for consumers. First mover in this niche becomes the default citation source — every future superbug news story links to “Bug Report’s pathogen profile for [bacteria].”

Timing: Post-Lancet 39M study (2024), post-WHO GLASS dashboard update (2025), pre-WHO antimicrobial awareness week (Nov 2026). The awareness window is open and nobody has built the definitive consumer resource yet.

Compounding moat: Every week of data collection makes the historical trend analysis more valuable. By month 12, Bug Report has the most comprehensive longitudinal consumer-facing AMR dataset on the internet.

Risk & Mitigation